Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Aflibercept

Nature Reviews Drug Discovery volume 11, pages 269–270 (2012)Cite this article

Subjects

Abstract

In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stewart, M. W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc. 87, 77–88 (2012).

    Article  CAS  Google Scholar 

  2. Narayanan, R. et al. Ranibizumab. Nature Rev. Drug Discov. 5, 815–816 (2006).

    Article  CAS  Google Scholar 

  3. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393–11398 (2002).

    Article  CAS  Google Scholar 

  4. US Food and Drug Administration. FDA labeling information — Eylea. FDA website [online], (2011).

  5. Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897–1908 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Michael W. Stewart is at the Department of Ophthalmology, Mayo Clinic, Mayo School of Medicine, Jacksonville, Florida 32224, USA.,

    Michael W. Stewart

  2. Seden Grippon is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,

    Seden Grippon

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. Stewart.Michael@mayo.edu; SGrippon@imscg.com; p.kirkpatrick@nature.com,

    Peter Kirkpatrick

  4. SGrippon@imscg.com,

    Peter Kirkpatrick

Authors
  1. Michael W. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seden Grippon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

M.W.S has served on an advisory board and received research support from Regeneron, served on an advisory board for Allergan, and received research support from Bayer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, M., Grippon, S. & Kirkpatrick, P. Aflibercept. Nat Rev Drug Discov 11, 269–270 (2012). https://doi.org/10.1038/nrd3700

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3700

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research